腹腔热灌注化疗联合免疫治疗在恶性腹水中的应用

临床肿瘤学杂志

腹腔热灌注化疗联合免疫治疗在恶性腹水中的应用

王俞，崔书中，巴明臣

510095 广州广州医科大学附属肿瘤医院腹外二科暨体腔热灌注治疗中心

收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2013-11-30 发布日期:2013-11-30

The clinical applications of HIPEC plus immunotherapy in the malignant ascites

WANG Yu，CUI Shuzhong， BA Mingchen.

Department of Abdominal Surgery （Section 2） and Intracelom Hyperthermic Perfusion Therapy Center， Cancer Hospital of Guangzhou Medical College， Guangzhou 510095， China

Received:1900-01-01 Revised:1900-01-01 Online:2013-11-30 Published:2013-11-30

摘要/Abstract

摘要：

腹腔热灌注化疗（HIPEC）作为治疗进展期胃癌、结直肠癌及卵巢癌等腹腔肿瘤合并恶性腹水的有效措施，已广泛应用于临床。有国内外学者对腹腔肿瘤合并恶性腹水患者行HIPEC后，再辅以免疫治疗（腹腔内常温灌注白介素2、干扰素等免疫制剂），收到了更好的临床疗效，提示HIPEC联合免疫治疗是一种更为科学的综合治疗方法。本文旨在对HIPEC联合免疫治疗在恶性腹水中的应用研究进展作一综述。

Abstract: Hyperthermic intraperitoneal chemotherapy （HIPEC）， a promising treatment modality for advanced gastric cancer， colorectal cancer， ovarian cancer and other abdominal malignant tumors with ascites， has been widely used in the clinic. The HIPEC supplemented by immunotherapy with intraperitoneal perfusion of interleukin2， interferon and other immune agents appears to be a feasible and effective treatment for malignant ascites. The combination of HIPEC and immunotherapy can be regarded as a scientific and comprehensive treatment. This review will focus on the clinical applications of HIPEC plus immunotherapy for the treatment of malignant ascites.

王俞，崔书中，巴明臣. 腹腔热灌注化疗联合免疫治疗在恶性腹水中的应用[J]. 临床肿瘤学杂志, 2013, 18(11): 1041-.

WANG Yu，CUI Shuzhong， BA Mingchen.. The clinical applications of HIPEC plus immunotherapy in the malignant ascites[J]. Chinese Clinical Oncology, 2013, 18(11): 1041-.

参考文献

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed